A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Human Immunodeficiency Virus and Herpesviridae
Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK2248761 WBM Capsule
DRUG: GSK2248761 WBM Tablet Formulation 1
DRUG: GSK2248761 WBM Tablet Formulation 2
DRUG: GSK2248761 WBM Tablet Formulation 3
DRUG: GSK2248761 WBM Tablet

Sponsor

ViiV Healthcare

Collaborators

[object Object]